Credits: Canva
The US Food and Drug Administration has approved TNKase or Tenecteplase, which is a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke in adults.
Ischemic strokes happen when a blood clot blocks a blood vessel in your brain. It can cause permanent brain damage and death. If enough brain cells die, you can also lose the abilities or body functions those cells control. They are also the most common types of stroke, with 80% of all strokes being ischemic strokes.
It is delivered as a single five-second intravenous bolus, which is faster than the standard of care Activase or alteplase, which is administered as an intravenous bolus followed by a 60-minute infusion. The manufacturer of TNKase, Genetech said a new 25-mg vial configuration will also be available in the coming months.
The approval came at the backdrop of a study that compared TNKase to Activase in patients with acute ischemic stroke. These patients also presented with a disabling neurological deficit. Results show that TNKase was comparable to Activase in terms of efficacy and safety.
In the United States it self, it affects more than 795,000 people each year and is the leading cause of long-term disability. It is also the fifth leading cause of death. Since brain damage can happen if this progresses rapidly, one needs an immediate, fast-acting medical care.
TNKase thus provide a faster and simpler administration which can be critical for anyone. The chief medical officer and head of global product development at Genetech, Levi Garraway, MD., PhD., said, "Today's approval is a significant step forward and underscores our commitment to advancing stroke treatment options for patients."
Some of the most common symptoms include weakness or paralysis on one side of your face and body. You may also feel trouble speaking or have loss of speech, also known as aphasia. You may faced slurred or garbled speaking, also known as dysarthria. Other symptoms include loss of muscle control on one side of your face, or sudden worsening or loss of your senses, including vision, hearing, smell, taste, and touch.
While these are symptoms one has who is prone to this condition. However, often, many may confuse it with other illnesses. It is best to keep an eye out for warning signs. These could be looking out for yourself or your loved one. Note if there is a sudden loss of balance. Look out for sudden vision loss or changes in one or both eyes. Look for a droop on one or both sides of your face, especially when you smile. Raise both arms and see if one arm sags or drops in a way it usually does not. Note for your speech. Are you as fluent? Are you have trouble speaking? If you see any of such signs, start tracking it and talk to your healthcare provider.
Credit: AI
The COVID-19 pandemic did more than overwhelm global healthcare systems. It also disrupted timely care for people experiencing strokes.
Published in European Medical Journal, a global review of 107 studies has found that patients delayed hospital visits, stroke-related hospital admissions fell and treatment became harder to access during the pandemic.
The review, which examined research published between December 2019 and September 2024, looked at how the pandemic affected stroke care from the moment symptoms began through hospital treatment and recovery. Researchers initially screened 1,405 studies before including 107 in their analysis.
One of the alarming patterns among stroke victims was a delay in seeking medical help. People experiencing stroke symptoms were reluctant to go to hospitals because they feared catching COVID-19 or believed healthcare facilities were already overwhelmed.
The delay was particularly noticeable among people with milder stroke symptoms; some of whom reached hospitals after critical treatment windows had passed.
The findings are a cause of concern as stroke treatment is extremely time-sensitive. Delays can prevent patients from seeking timely treatments to restore blood flow to the brain.
Several studies included in the review reported a decline in stroke admissions during the pandemic. One study found a 31% decrease in monthly admissions for ischaemic stroke, while another reported a 44% reduction.
The drop did not mean fewer people were having strokes. Instead, researchers found evidence that some patients may simply have avoided or delayed seeking emergency care.
When patients did reach hospitals, several studies found they were more likely to have more severe strokes than patients treated before the pandemic.
Also read: Innovations in Structural Heart Care: The Shift Towards Minimally Invasive Therapies
The disruption was not limited to patients' decisions about when to seek help. Hospitals had to reorganise resources and reassign staff towards COVID-19 response. These changes affected stroke services and contributed to delays in treatment.
The review also identified increases in both symptom-to-door time, the period between stroke symptoms beginning and reaching hospital, and door-to-treatment time, the period between arriving at hospital and receiving treatment to restore blood flow. Ambulance services also faced additional pressure during the pandemic.
The review found evidence that the disruption was associated with poorer outcomes for some stroke patients. One study reported significantly greater disability at discharge during the pandemic, with a median modified Rankin Scale score of 4 compared with 2 before the pandemic. The difference remained at three months after the stroke.
Another analysis reported higher mortality at discharge among patients treated during the pandemic, at 7.7% compared with 2.5% in a pre-pandemic group.
Telemedicine refers to seeking healthcare remotely using technology, without the doctor and patient needing to be in the same physical location.
Telemedicine helped maintain some continuity of stroke care during the pandemic, but access was not even everywhere.
The review found that younger patients were more likely to use remote healthcare services, while older adults didn't.
This raises concerns about whether telemedicine can adequately support people who may have greater healthcare needs but face barriers to digital access.
The researchers added that said future preparedness should focus on keeping stroke services accessible, ensuring equitable access to telemedicine and educating patients about the need to seek emergency care promptly.
Credit: AI
A few extra minutes during an upper gastrointestinal endoscopy may help doctors detect more gastric cancers and precancerous alternations, according to research recently discussed at the World Congress of Gastroenterology (WCOG) 2026 in New Delhi.
At WCOG, it was discussed that the quality and duration of an endoscopic examination can influence the chances of finding early cancer. An inspection time of an additional at least seven minutes was linked with about 3.4 times higher detection of gastric cancer and dysplasia.
The finding comes as gastrointestinal cancers continue to increase, contributing to a growing global health burden. GI cancers currently account for around one in four cancer cases and one in three cancer deaths worldwide. The overall burden of the disease is projected to nearly double by 2050.
Dr. Pramod Garg, Professor & Head, Department of Gastroenterology and Human Nutrition, AIIMS, New Delhi; President, Indian Society of Gastroenterology and Co-Chair, Steering Committee, WCOG 2026, said, “Earlier detection depends on both identifying people at risk and ensuring that diagnostic procedures are performed to the highest possible standard. High-quality endoscopy can create an important opportunity to identify disease at a stage when intervention can make a greater difference.”
Also read: WCOG 2026: How Infections, Metabolic Disease Are Changing Digestive Health
An upper gastrointestinal endoscopy allows doctors to examine the lining of the oesophagus, stomach, and upper part of the small intestine using a flexible camera device.
Simply inserting the scope and looking quickly may not be enough to identify subtle abnormalities. A more systematic examination allows the endoscopist more time to examine the stomach lining, identify suspicious areas, improve mucosal visualisation and document findings accordingly.
The WCOG discussion therefore puts focus on not just whether endoscopy is performed, but also on how long and how well it is performed.
The reported 3.4 times association highlights the value of a careful, detailed examination that could help detect changes related to cancer early, prompting timely treatment.
Also read: Fatty Liver, Chronic Gut Diseases And Worm Infections: India’s Changing Disease Burden
The changes in India's gastrointestinal cancer burden were also discussed, including growing concern around early-onset colorectal cancer. Researchers are examining whether genetics, environmental exposures and changes in the gut microbiome could be contributing to colorectal cancer appearing at younger ages.
WCOG 2026 also included concerns related gallbladder cancer, liver cancer and the rising role of metabolic risk factors. Discussions also focused on the use of AI in gastrointestinal diagnosis and the importance of validating these tools before introducing them in standard practice.
Dr. Govind Makharia, Professor, Department of Gastroenterology and Human Nutrition, AIIMS, New Delhi and Chairman, Local Organising Committee, WCOG 2026, said, “AI has the potential to strengthen diagnosis and decision-making across gastroenterology, while advanced endoscopy is expanding what can be treated through minimally invasive approaches. The next step is ensuring that these technologies are supported by robust evidence and integrated responsibly into clinical practice.”
H. pylori was also addressed as a preventable risk factor for gastric cancer.
Dr Barry Marshall, Nobel Laureate in Physiology or Medicine, said, “H. pylori is much more than an ulcer organism. If the infection persists for many years, it can cause chronic inflammation in the stomach and increase the risk of gastric cancer. That gives us an opportunity because this is a potentially preventable cause of cancer.”
Advances in minimally invasive procedures like POEM, endoscopic submucosal dissection and therapeutic EUS were also discussed, although access to advanced GI care remains uneven.
Credit: X
The President of the United States, Donald Trump, has revealed that he takes aspirin every day, sharing that he has been doing so for decades because he believes it helps keep his blood “thin”.
He said it while discussing his aspirin use and the bruising that was recently seen on his knuckles. He also said that doctors have advised he take a lower dose.
“I take an aspirin a day. I don’t know if it works but psychologically I need it. It thins the hell out of your blood I guess. I don’t know if it works or not but I’ve been doing it for a long time. And here I am making speeches. I like Bayer aspirin. And I take the big one. They want me to go down to the 80. I take the 386. I don’t know what the hell it is. It’s a monster. They said, ‘Sir, you don’t need that!’ I said, do me a favor, I’ve been doing okay for 35 years. Leave me alone.”
So, does taking an aspirin every day actually protect the heart? And if yes, does a higher dose necessarily provide better results?
Aspirin affects platelets, which are tiny components of blood that help form clots. By making platelets less likely to clump together, aspirin can reduce the formation of blood clots that could block an artery supplying the heart or brain.
This is why doctors may prescribe daily aspirin to people who have already had a heart attack, stroke, or procedures like coronary stent placement.
But aspirin does not make the blood “thin” in a literal sense. It changes the way blood platelets clot. The US Food and Drug Administration (FDA) says daily aspirin can help people with cardiovascular disease or those who have already had a heart attack or stroke, but daily use is not suitable for everyone.
Aspirin can reduce the risk of certain blood clot formations, but it can also increase the risk of unwanted bleeding. The FDA warns that aspirin can lead to serious side effects like bleeding in the stomach and brain.
It recommends that people do not take daily aspirin without discussing it first with their healthcare professionals.
Mayo Clinic also says that daily aspirin is not right for everyone. Regular use can increase the risk of gastrointestinal bleeding and stomach ulcers, while in some people it can also increase the risk of a bleeding stroke.
For people who have never had a heart attack or stroke or any other type of cardiovascular disease, taking aspirin routinely to prevent a cardiovascular event is generally not recommended.
The American Heart Association says routine daily aspirin is not recommended for most healthy adults without cardiovascular disease because its benefit can be offset by the risk of serious bleeding.
The FDA also says that for people without cardiovascular disease risk, the risks of long-term aspirin use may be greater than the benefits.
For someone who has already had a heart attack, stroke or any other cardiovascular event, doctors may prescribe daily aspirin because preventing another clot-related event can outweigh the bleeding risk.
According to Mayo Clinic, this is a secondary method of prevention. It says that the benefit of daily aspirin in this group is well established. This does not mean that patients should start, stop or change their aspirin dose on their own.
Also read: White House Chief Of Staff Susie Wiles Reveals Brutal Toll Of Fighting Cancer
A higher dose does not automatically provide better protection against heart attacks. Low-dose aspirin prescribed for cardiovascular health is usually around 75 to 100 mg, with 81 mg frequently used.
Mayo Clinic says that the appropriate dose depends on the individual and should be discussed with a healthcare professional.
Taking higher doses of aspirin can increase the risk of bleeding. People with a history of stomach ulcers or gastrointestinal bleeding, bleeding disorders or aspirin allergy may also face greater risks.
The risk of bleeding also increases with age. The American Heart Association says routine aspirin for primary prevention is generally not recommended for healthy adults over 70.
© $2026 Times Horizon Private Limited